Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities.
Scientific Congress Publications
Supported by Bayer Pharmaceuticals
ESC 2026
Cardiovascular-kidney-metabolic overlap and finerenone in heart failure: insights from the FINEARTS-HF Trial
- Coexistence between HFmrEF/HFpEF and other CKLM domains was effectively universal in FINEARTS-HF, globally and in all age groups.
- Higher CKLM overlap was incrementally associated with higher rates of adverse cardiovascular, kidney, metabolic, and mortality outcomes.
- CKLM status did not appear to modify the benefits of finerenone on CV death and total HF events.
These findings underscore the importance of integrative approaches to screening and management of CKLM conditions in HFmrEF/HFpEF, and the potential of finerenone to reduce adverse outcomes across this spectrum.
© 2026 Bayer. All rights reserved.
Bayer and the Bayer Cross are registered trademarks of Bayer.
Copies of the Bayer Pharmaceuticals supported presentations obtained from this platform are for personal use only and may not be reproduced or distributed without permission from the authors.
Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities, and the presentations are shared in the interest of scientific exchange.
For any questions, please contact Medical Information at https://www.medicalinformation.bayer.com/
PP-GEN-ALL-0014-1
